المؤلفون: Lemech, Charlotte, Williams, Rachel, Thompson, Stephen, McCaughan, Brian, Chin, Melvin

مصطلحات موضوعية: Follicular dendritic cell sarcoma, BRCA2 mutation, Veliparib, Case report

العلاقة: http://www.biomedcentral.com/1756-0500/9/386Test

الإتاحة: http://www.biomedcentral.com/1756-0500/9/386Test

المؤلفون: Niravath, Polly, Eble, Tanya, Contreras, Alejandro, Li, Marilyn, Franco, Luis M, Rimawi, Mothaffar

مصطلحات موضوعية: BRCA2 mutation, Small cell carcinoma of the breast, PIK3CA mutation, Therapeutic stress

العلاقة: http://www.ehoonline.org/content/4/1/1Test

الإتاحة: http://www.ehoonline.org/content/4/1/1Test

المؤلفون: Hartley, Taila, Cavallone, Luca, Sabbaghian, Nelly, Silva-Smith, Rachel, Hamel, Nancy, Aleynikova, Olga, Smith, Erika, Hastings, Valerie, Pinto, Pedro, Tischkowitz, Marc, Tomiak, Eva, Foulkes, William D

مصطلحات موضوعية: PALB2, Hereditary breast cancer, Pancreatic cancer, Melanoma, BRCA1 and BRCA2 mutation-negative

العلاقة: http://www.hccpjournal.com/content/12/1/19Test

الإتاحة: http://www.hccpjournal.com/content/12/1/19Test

المصدر: A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06395519Test

المصدر: A Phase I/II, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of ACE-86225106 as Monotherapy in Patients With Advanced Solid Tumors

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06380660Test

المؤلفون: Stemline Therapeutics, Inc., GlaxoSmithKline

المصدر: Robson M, SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, LW, Tung N, Armstrong A, Wu W, Goessl C, Runswk S, Conte P. Olapar for Metastat Breast Cancer Patnts wh a Germle BRCA Mutatn. N Engl J Med. 2017 Aug 10;377(6):523-533. do 10.1056/NEJMoa1706450. Epub 2017 Jun 4. Erratum : N Engl J Med. 2017 Oct 26;377(17 ):1700.
Lton JK, Rugo HS, Ettl J, Hurvz SA, Goncalves A, Lee KH, Fehrenbacher L, YerushalmR, Ma LA, Mart M, Roche H, YH, Quek RGW, Markova D, Tudor , Hannah AL, Ermann W, Blum JL. Talazopar Patnts wh Advanced Breast Cancer and a Germle BRCA Mutatn. N Engl J Med. 2018 Aug 23;379(8):753-763. do 10.1056/NEJMoa1802905. Epub 2018 Aug 15.
Gelmon KA, Faschg PA, Couch FJ, Balmana J, Delaloge S, LabGaly Bennett J, McCutcheon S, Walker G, O'Shaughnessy J; Collaboratg vestators. Clal effecteness of olapar monotherapy germle BRCA-mutated, HER2-negate metastat breast cancer a real-world settg: phase LUCY ter analys. Eur J Cancer. 2021 Jul;152:68-77. do 10.1016/j.ejca.2021.03.029. Epub 2021 Jun 1.
Bard A, KaklamanV, Wks S, Wee A, Rhards D, Harb W, Osborne C, WesolowskR, KaruturM, Conklg P, Bagley RG, Wang Y, Conlan MG, Kabos P. Phase Study of Elacestrant (RAD1901), a Novel Selecte Estrogen Receptor Degrader, ER-Pose, HER2-Negate Advanced Breast Cancer. J Cl Oncol. 2021 Apr 20;39(12):1360-1370. do 10.1200/JCO.20.02272. Epub 2021 Jan 29.
Bard FC, KaklamanVG, Neven P, Streh G, Montero AJ, Forget F, Mouret-Reynr MA, Sohn JH, Taylor D, Harnden KK, Khong H, Kocs J, Dalenc F, Dlon PM, Babu S, Waters S, Deleu Garc Saenz JA, Br E, Cazzana M, Lu J, Aftos P, Cortes J, L S, TonG, Laurent D, HabboubN, Conlan MG, Bard A. Elacestrant (oral selecte estrogen receptor degrader) Versus Standard Endocre Therapy for Estrogen Receptor-Pose, Human Epermal Growth Factor Receptor 2-Negate Advanced Breast Cancer: Results From the Randomed Phase EMERALD Trl. J Cl Oncol. 2022 Oct 1;40(28):3246-3256. do 10.1200/JCO.22.00338. Epub 2022 May 18. Erratum : J Cl Oncol. 2023 Aug 10;41(23):3962.
Turner NC, Balmana J, Poncet C, GoultT, Tryfon K, Honkoop AH, ZoppolG, Raz E, Johannsson OT, ColleonM, Tutt AN, Audeh W, natd M, Malz A, Tredan O, Musolo A, Vuylsteke P, Juan-Fa MJ, Macpherson J, Kaufman B, Manso L, Goldste LJ, Ellard SL, Lang Jen KY, Adam V, Lre S, Erban J, Cameron DA; BRAVO Steerg Commtee and the BRAVO vestators. Napar for Advanced Breast Cancer wh Germle BRCA1 and BRCA2 Mutatns: the EORTC 1307-BCG/B5-13/TESARO PR-30-50-10-C BRAVO Study. Cl Cancer Res. 2021 Oct 15;27(20):5482-5491. do 10.1158/1078-0432.CCR-21-0310. Epub 2021 Jul 22.
Mza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote Ben-Baruch NE, Marth C, Madry R, Chrtensen RD, Berek JS, Dorum A, Tker AV, du Bo A, Gonzalez-Mart A, Follana P, Benno B, Rosenberg P, Gbert L, Rel BJ, Buscema J, Balser JP, Agarwal S, Matulon UA; ENGOT-OV16/NOVA vestators. Napar Matenance Therapy Platum-Sense, Recurrent Ovarn Cancer. N Engl J Med. 2016 Dec 1;375(22):2154-2164. do 10.1056/NEJMoa1611310. Epub 2016 Oct 7.
Phase II Study Evaluating the Addition of Elacestrant, an Oral Selective Estrogen Receptor Degrader (SERD), to Niraparib, a PARP-inhibitor, Compared to Niraparib Alone in Patients With Hormone Receptor (HR)-Positive, HER2-negative Locally Advanced or Metastatic Breast Cancer With g/tBRCA1/2 and/or g/tPALB2 Mutations

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06201234Test

Other URLs: http://gbg.deTest

المؤلفون: National Cancer Institute (NCI)

المساهمون: Pamela Munster, Principal Investigator

المصدر: A Phase I/Ib Study of Olaparib and ASTX727 in BRCA1/2- and HRD-mutated Tumors

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06177171Test

المصدر: Contribution of Oncogenetics in Breast Cancer in Reunion Epidemiology of Breast Cancer in Reunion: Study of the Reunion Mutation on BRCA2

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05898009Test

المساهمون: FABI ALESSANDRA, Principal Investigator, Director of Unit of Precision Medicine in Breast Cancer

المصدر: Endocrine Disruptors and Life STILe in Patients Carrying BRCA Pathogenic VAriants With Breast and/or Ovarian CAncer and Women Without Neoplasm: the STILVARCA Study

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05748353Test

المؤلفون: GlaxoSmithKline

المساهمون: Pamela Munster, Principal Investigator

المصدر: Combination Therapy of Niraparib and Irinotecan in Cancers With Mutations in DNA Repair Genes

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05694715Test